Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

AstraZeneca’s (AZN) Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with resectable non-small cell lung cancer, NSCLC ...

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

bladder cancer, mesothelioma and others. In Study 22, the tremelimumab/Imfinzi regimen achieved a median overall survival (OS) of 18.7 months, a finding which AZ’s head of oncology R&D José ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...